A B S T R A C T The contact phase of intrinsic clotting involves Factor XI, Factor XII, Fletcher factor, and a fourth activity that we call contact activation cofactor (CAC). All four of these activities are reduced or absent in Dicalite-adsorbed plasma. A modified activated partial thromboplastin time assay for CAC has been defined by using a substrate of Dicalite-adsorbed plasma combined with partially purified sources of Factors XI and XII, and Fletcher factor. The following properties of CAC in plasma have been determined by using the assay: it is stable up to 60 min at 56°C; gradually loses activity at 800C; is stable between pH 6 and 9; is precipitated by ammonium sulfate between 40% and 50% saturation; is slightly adsorbed by Al (OH) s; and is eluted from DEAE-cellulose after the major protein peaks. A purification procedure has been devised that separates CAC from other known clotting factors. Isolated CAC was less stable than CAC in plasma, but in the presence of dilute human serum albumin it retained full activity for 80 min at 560C. On gel filtration CAC had an apparent mol wt of 220,000 daltons. These properties are consistent with those described for Fitzgerald factor, which further supports the conclusion that CAC and Fitzgerald factor represent the same activity. Isolated CAC promoted the generation of activated Factor XI (XIa) in a mixture containing purified Factor XI, Factor XII, and kaolin. The amount of Factor XI. generated was proportional to the amount of added CAC. No time-consuming reaction between Factor XI or Factor XII and CAC could be demonstrated.
INTRODUCTION
When decalcified plasma is exposed to an activating surface such as glass, intrinsic clotting is initiated Dr. Schiffman is an Established Investigator of the American Heart Association.
Received for publication 27 January 1975 and in revised form 10 July 1975. through a series of reactions referred to collectively as the contact activation phase of intrinsic clotting. Initially, Factors XI and XII were thought to be the sole reactants, with Factor XII being adsorbed and activated at the surface and then enzymatically activating
Factor XI (1) (2) (3) . However, the picture became more complex with the description of Fletcher factor, which also participated in contact activation (4, 5) . Recently, we have demonstrated that an additional plasma activity participates in the interaction of Factors XI and XII in the presence of Fletcher factor and an activating surface (6) . We call this activity contact activation cofactor (CAC).' CAC, like the other contact activation factors, is readily adsorbed to glasslike surfaces.
This property allows one to prepare an artificial assay system for CAC activity. Below we report the details of this assay, some of the properties of CAC activity in plasma, a method for partial purification that separates CAC from other characterized clotting factors, and some properties and reactions of the isolated CAC.
METHODS
All plasmas and plasma fractions were protected from contact with glass surfaces. Plastic equipment was used whenever possible. Essential glass surfaces (cuvettes, columns) were coated with Siliclad (Clay Adams, Div. of Becton, Dickinson & Co., Parsippany, N. J.). Platelet-poor plasmas were prepared from blood taken into either balanced citrate anticoagulant (0.06 M sodium citrate plus 0.04 M citric acid) or acid citrate dextrose anticoagulant by centrifugation at 12,500 g for 10 min.
Factor XI-Fletcher factor reagent for CAC assay was the pooled first protein peak from the DEAE-cellulose chromatography of normal plasma or normal plasma adsorbed once with Al (OH)8, prepared as described previously (7) . This technique separates Factor XI with Fletcher factor from other known clotting activities. The 'Abbreviations used in this paper: CAC, contact activation cofactor, TES, N-tris (hydroxymethyl) methyl-2-aminoethane sulfonic acid. Activated clotting factors are designated by the subscript "a"; e.g. Factor XI., activated Factor XI.
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Factor XII reagent for CAC assay. Factor XII was separated from other known clotting factors by DEAEcellulose chromatography of normal plasma or normal plasma adsorbed once with Al (OH)s either by the techniques previously described or by a slight modification thereof (7) . Saturated ammonium sulfate solution was added to the pooled Factor XII fraction to 25% saturation. The precipitate was discarded, and the solution was brought to 50% saturation. The 50% precipitate, containing the Factor XII, was dissolved in a small amount of buffer and dialyzed to remove ammonium sulfate. This process concentrated Factor XII and largely separated it from anti-XIa (8) . The reagent used for most of these experiments was further rechromatographed on DEAE-cellulose. The final reagent, purified about 3.4-fold over starting plasma, was diluted to about 42%, of pooled normal plasma Factor XII activity and stored at -20'C in plastic vials.
Dicalite-adsorbed plasma was prepared by chromatographing normal citrated plasma on a column of the diatomaceous earth powder Dicalite 4200 (Grefco Inc., Dicalite Div., Los Angeles, Calif.). The Dicalite was washed five times with distilled water and five times with N-tris (hydroxymethyl) methyl-2-aminoethane sulfonic acid (TES) buffer (0.05 M TES and 0.1 M NaCi, pH 7.35) by suspending the powder in wash solution, allowing the major fraction to settle, and decanting the supernate. The washed powder was then suspended in TES buffer, and the slurry was used to build a column (1-1.1 g Dicalite/ml plasma). Normal citrated plasma was added to the column, and the column was eluted with TES buffer. The major protein peak was pooled (about 1-1.2 times the volume of applied plasma) and incubated at 370C in glass tubes for up to 2 h until the partial thromboplastin time (9) of the plasma in the presence or absence of kaolin rose to around 150 s.
The pH was adjusted to 7.4, and the Dicalite-adsorbed plasma was packed in small samples in plastic vials and frozen at -200C. The reagent used for most of the experiments reported herein had the following clotting factor activities: Factor II, 63%; factor V, 30%; Factor VIII, 62%; Factor IX, 103%o; Factor X, 92%o; Factor XI, 4%; Factor XII, 0.6%o; Fletcher factor, 0.1%o, and fibrinogen, 105 mg/100 ml.
When the diluted Factor XI-Fletcher factor reagent and diluted Factor XII reagent were added to Dicalite-adsorbed plasma in the presence of cephalin, kaolin, and calcium, the clotting times observed were longer than those obtained with diluted congenital Factor V-deficient plasma as a source of Factor XI, Factor XII, and Fletcher factor as well as other clotting activities (see Table I ). Factor Vdeficient plasma was used to supply missing clotting factor activities to eliminate the possibility that any decrease in clotting time might be due to supplementing the reduced Factor V in the substrate. Since the clotting times in the presence of this plasma were shorter than the clotting times obtained with isolated Factors XI and XII, and Fletcher factor, and Dicalite-adsorbed plasma contained adequate amounts of the other known clotting factors, the diluted Factor V-deficient plasma must be supplying another missing activity to the system. We define this additional activity missing in the Dicalite-adsorbed plasma as CAC.
Absence of CAC in Dicalite-adsorbed plasma was confirmed by failure of Dicalite-adsorbed plasma to promote generation of Factor XI. in a mixture containing Factor Clotting mixtures 1 and 2 contained 0.01 ml cephalin 1/10, 0.05 ml Dicalite-adsorbed plasma, 0.05 ml diluted Factor XIFletcher factor reagent, 0.05 ml diluted Factor XII reagent, 0.05 ml TES buffer, and 0.01 ml 20 mg/ml kaolin. Clotting mixture 3 contained 0.01 ml cephalin 1/10, 0.05 ml Dicaliteadsorbed plasma, 0.05 ml diluted Factor V-deficient plasma, 0.1 ml TES buffer, and 0.01 ml 20 mg/ml kaolin. Clotting mixture 4 contained 0.01 ml cephalin 1/10, 0.05 ml Dicaliteadsorbed plasma, 0.15 ml TES buffer, and 0.01 ml 20 mg/ml kaolin. After 10 min incubation at 370C, 0.025 ml 25 mM CaCl2 was added and the clotting times noted. The Factor V deficient plasma contained 75% Factor XI, 84% Factor XII activity and 96% Fletcher factor. Average of two experiments.
XI-Fletcher factor reagent and Factor XII adsorbed to kaolin. The reaction system was that described previously (6) .
CAC assay. The CAC assay was based on the ability of a test substance to correct the abnormal clotting time of a substrate containing Dicalite-adsorbed plasma and partially purified Factors XI, XII, and Fletcher factor in the presence of cephalin, calcium chloride, and kaolin as an activating surface. This substrate contains all known clotting factors except CAC. The reagents were added to a plastic clotting tube in the following order: 0.01 ml cephalin (10), diluted 1/10 in barbital buffer, pH 7.35; 0.05 ml Dicalite-adsorbed plasma; 0.05 ml Factor XIFletcher factor reagent; 0.05 ml Factor XII reagent; 0.05 ml test substance; and 0.01 ml kaolin (20 mg/ml) (kaolin, N.F. colloidal, Mallinckrodt Chemical Works, St. Louis, Mo.). A stopwatch was started with the addition of the kaolin, the tube was placed in a heating block at 370C, and precisely 10 min later 0.025 ml CaCl2 (either 100 mM in early experiments or 25 mM for the later experiments) was added, and the clotting time was noted. A standard curve was prepared by recording the log clotting time of a normal standard plasma diluted in TES buffer against log plasma concentration. Samples for assay were dialyzed against and/or diluted in TES buffer.
Other clotting factor assays. Assays for Factors II, V, VIII, IX, X, XI, XII, and Fletcher factor have been described in detail elsewhere (6 Estimation of molecular size by gel filtration. Samples were chromatographed on a column of Sephadex G-200, 2.5 X90 cm, with 1 cm of Sephadex G-25 layered on the top. The column was equilibrated and eluted with 1.5 M NaCl-0.025 M Tris, pH 7.2, containing partially purified human serum albumin to produce an A21W= 0.1. Fractions of 3.5 ml were collected automatically. The column was standardized with human gamma globulin (Pentex Biochemical, Kankakee, Ill.), which gel filters as a molecule of 205,000 daltons (13); aldolase (Pharmacia Laboratories, Inc., Piscataway, N. J.) 158,000 daltons; bovine serum albumin (Worthington Biochemical Corp., Freehold, N. J.) 70,000 daltons; and chymotrypsinogen A (Pharmacia) 25,-000 daltons. Void volume was defined by blue dextran (Pharmacia). A standard curve was prepared by plotting log molecular weight against elution volume/void volume (13) .
Partially purified human serum albumin used in these systems was prepared from the Calbiochem (San Diego, Calif.) crystalline B-grade albumin by binding to DEAEcellulose at pH 7.2, 0.02 M barbital or Tris, and 0.03 M NaCl. After washing the column with six column volumes of buffer or until protein effluent fell to background, the albumin was eluted with 0.8 M NaCl in buffer and stored in concentrated solution at -200C. At concentrations used for experiments below it had no detectable Factor II, V, VIII, IX, X, XI, XII, Fletcher factor, or CAC activity.
Purified Factor XI was prepared from normal plasma by a slight modification of a previously described technique (6) . Plasma was chromatographed on DEAE-cellulose; the isolated Factor XI was adsorbed to and eluted from BaSO4, then chromatographed on SP-Sephadex at pH 5.2 with a linear gradient between 0.05 M sodium acetate-0.0001 M EDTA containing 0.05 M NaCl and the same buffer containing 0.5 M NaCl; the resultant Factor XI fraction was chromatographed on Dicalite 4200 in the presence of human serum albumin (Calbiochem, crystalline, B-grade) and concentrated by ultracentrifugation. The purified Factor XI fraction had a specific activity of about 5,600 (% Factor XI/A28o), which represented a purification of about 3,500-fold over normal plasma. A diluted sample that clotted in the kaolin-activated Factor XI assay in 75 s produced a clotting time of 235 s in the absence of an activating surface. At the time of use, this fraction contained about 300% Factor XI activity. When diluted to about 20% Factor XI activity, it had no detectable Factor II, VIII, IX, or X activity; factor V, about 0.1%o; Fletcher factor, about 0.1%; Factor XII, less than 0.1%. At 8% Factor XI, it had much less than 0.1%o CAC. The fraction was diluted to desired concentrations in solutions containing purified human serum albumin at a concentration producing Am =0.1.
Purified Factor XII. Normal plasma, dialyzed against a pH 7.2 buffer containing 0.02 M Tris, 0.03 M NaCl, and 50 pug/ml Polybrene (hexadimethrine bromide, Aldrich Chemical Co., Inc., Milwaukee, Wis.) was chromatographed on DEAE-cellulose equilibrated with this buffer. The Factor XII fractions, which eluted after the first protein peak, were pooled and adsorbed to DEAE-Sephadex A-50equili-brated with pH 8.1 buffer containing 0.01 M Na2HPO4, 0.005 M EDTA, and 50 ,g/ml Polybrene. Factor XII was eluted with a straight line gradient to pH 4.6 buffer containing 0.15 M NaH2PO4, 0.25 M NaCi, and 0.001 M EDTA according to the method of Revak, et al. (14) . The pooled Factor XII fraction, which eluted following the initial protein peak, had a specific activity of 595 (% Factor XII/A280). This represented a purification of about 370-fold over normal plasma. At a concentration producing a clotting time of 63 s in a kaolin-activated Factor XII (Table IV) . In some early experiments, assays were carried out with 100 mM CaCl2. The curves were reproducible, and the results were consistent. However, the clotting times were quite long, and the results could easily be affected by factors influencing available calcium ions. Therefore, 25 mM CaCl2 was selected for standard use.
The incubation time required to produce a minimum clotting time in this assay was quite long, around 15 Clotting mixtures contained 0.01 ml cephalin 1/10, 0.05 ml Dicalite-adsorbed plasma, 0.05 ml Factor XI-Fletcher factor reagent, 0.05 ml Factor XII reagent, 0.05 ml normal plasma diluted 1/20, and 0.01 ml kaolin. After 5 min incubation 0.025 ml of 25 mM CaCl2 was added and the clotting time noted. Fig. 3 . Since Factor V in the Dicalite-adsorbed substrate was somewhat reduced, the possibility existed that Factor V added in a test substance might reflect as apparent CAC activity. To test this possibility we assayed a partially purified Factor V preparation prepared as a by-product of CAC purification (see above). A fraction with 22% Factor V activity had only 0.8% apparent CAC activity. This small activity represented the maximum possible effect of Factor V in this assay; the effect may be even less, since the Factor V fraction may have contained some CAC. Therefore, an effect of factor V did not appear to be a significant problem in this assay unless a test material contained very high concentrations of Factor V. For greatest accuracy, fractions to be assayed for CAC activity should be di- CAC activity was relatively stable between pH 6 and 9 (see Table VI ). Exposure to pH 10 overnight resulted in significant loss of activity.
CAC activity precipitated from normal plasma between 40 and 50% saturation with ammonium sulfate (Table VII) . During this fractionation and subsequent dialysis, CAC activity was consistently lost. CAC was slightly adsorbed by Al(OH)3 (Table VIII) . Some properties of isolated CAC. The effect of temperature on partially purified CAC is shown in Table IX . At zero time, 0.01 ml of 20 mg/ml kaolin was added to a plastic tube containing 0.1 ml of each test reagent, and the sample was mixed well on a vortex mixer. At the times indicated, the sample was mixed again, and a 0.05-ml portion was removed and tested in the Factor XIa assay system as described in the text. The normal plasma contained 140% Factor XII, 125% Factor XI, 100% Fletcher factor, and 100% CAC. The Fletcher factor-deficient plasma contained 73% Factor XII, 87% Factor XI, and 78% CAC. cubation (line 3). Incubation of CAC with Factor XII produced no significant increase in apparent Factor XII activity, as shown in line 4. The effects of varying the concentration of CAC on the kinetics of generation of activated Factor XI in a reaction mixture containing Factors XI, XII, and CAC in the presence of kaolin are shown in Fig. 4 . Reducing the concentration of CAC in the reaction mixture produced a proportional drop in the amount of activated Factor XI formed. These results suggest that CAC may be consumed during the generation of activated Factor XI.
The effect of soluble trypsin on CAC was tested by incubating isolated CAC with trypsin at a concentration of 1.5-2.7 ug/ml in the reaction mixture. This concentration of trypsin rapidly activated the purified Factor XI, as we have demonstrated previously (6) . No increase in procoagulant activity occurred over 20 min, as detected in the CAC assay, in the absence of an activating surface.
DISCUSSION
Evidence for an additional activity that participated with Factors XI and XII in the contact phase of intrinsic clotting was first presented by us in 1960 (7). It was observed that the combination of partially purified plasma fractions containing Factor XI or XII was insufficient to correct the defect in Celite-adsorbed normal plasma, though adequate amounts of all other known INCUBATION TIME MIN FIGuRE 4 Effect of varying the concentration of CAC on the generation of Factor XIa in mixtures containing purified Factors XI, XII, and CAC. At zero time, 0.01 ml of 2 mg/ml kaolin was added to a mixture containing the equivalent of 0.1 ml of Factor XI (15%), 0.1 ml Factor XII (20%), and 0.1 ml CAC at one of the concentrations shown in the figure. The sample was well mixed on a vortex mixer, and at the times shown 0.05 ml samples were removed and tested for Factor XIa activity. A standard curve was made by testing dilutions of a mixture containing 14%o CAC sampled between 20 and 30 min incubation. The undiluted mixture was arbitrarily designated 100%. A plot of the log of the concentrations of the mixture versus the log of the clotting times formed a straight line, from which the other clotting times could be converted to percent. Confirmation of the unique nature of CAC was obtained by fractionation of normal human plasma according to the partial purification scheme outlined above. CAC activity separated from all the other known clotting activities. Furthermore, conditions of purification were relatively mild, and the other clotting activities could be recovered in fractions removed from the CAC fractions. Therefore, CAC activity was associated with a molecule clearly distinguishable from all other characterized clotting factors.
CAC was also differentiated from two components of the fibrinolysis system: plasminogen and Factor XII-cofactor (plasminogen proactivator). Factor XIIcofactor is a plasma activity through which Factor XII can initiate fibrinolysis. It elutes from anionic exchange resins with the Factor XI fraction (19, 20) . In contrast, CAC is bound to the resin at low ionic strength and elutes far beyond Factor XI in the presence of much higher salt concentrations, as shown above. Therefore, these two activities, which have rather similar names and both of which react with Factor XII, are quite different physically. The absence of detectable plasminogen-plasmin in partially purified CAC was important because plasmin can activate Factor XII (21) . Contamination of a CAC reagent with this activity could lead to spurious results in reaction mixtures containing Factor XII.
For each previously defined clotting factor, rare patients have been identified who have a congenital de- ficiency of that activity. Therefore, one might expect to find a CAC-deficient patient. Recently, a new clotting abnormality has been described known as Fitzgerald trait (22) . Mr. Fitzgerald's plasma had a defect in the contact phase of intrinsic clotting that could not be explained by the absence of a known contact factor-Factor XI, Factor XII, or Fletcher factor. The activity lacking in this plasma was called Fitzgerald factor. We have tested this plasma in our assay system and found that it lacks CAC and that it is corrected by partially purified CAC (23) . Therefore, Mr. Fitzgerald appears to be the first recognized CAC-deficient patient.
Added evidence for the identity of CAC and Fitzgerald factor is found in a comparison of some of the properties recently described for Fitzgerald factor (24) (15, 16, 18, 21, 25) . CAC may represent a third link between these two interrelated systems.
CAC shares another important characteristic with Factor XII and Fletcher factor. Patients lacking these activities have no known hemostatic abnormality (3, 4, 22) . Hence, none of these activities seems to be required for normal clotting in vivo. The clotting reactions of Factor XII, Fletcher factor, and CAC that are studied in vitro may occur in vivo, but presumably alternate physiologic pathways also exist that can lead to the activation of Factor XI.
The experiments described above provide some insights into the role of CAC in the generation of Factor XIa. We have shown previously that CAC activity promotes activation of Factor XI in mixtures containing Factors XI, XII, and Fletcher factor (6). Herein we demonstrate that CAC alone is able to promote generation of Factor XIa in mixtures containing purified Factors XI and XII in the presence of kaolin. Both isolated CAC and the CAC activity in diluted Fletcher factordeficient plasma were effective. The purified Factor XI reagent used in these experiments at 10% activity contained about 0.05% Fletcher factor activity, and the purified Factor XII reagent at 10% activity contained 0.1% Fletcher factor. Therefore, it is not possible to exclude an effect of traces of Fletcher factor. However, the results strongly suggest that CAC is a primary cofactor for this reaction.
Kinetic studies of the mechanism of interaction of CAC with Factors XI and XII in the presence of kaolin indicate that the amount of product formed is proportional to the amount of CAC present. Therefore, one might expect that CAC forms a complex with one of the other reactants that limits the amount of product formed. However, we could demonstrate no time-consuming preliminary reaction between either Factor XI or Factor XII and CAC in the presence of kaolin with Factor XI-or Factor XII-deficient plasma as substrate (Table XI) . In one experiment, mixtures containing CAC and either Factor XI or factor XII were tested with Fitzgerald-deficient 1090 S. Schiffman and P. Lee plasma as substrate. Both reaction mixtures showed a decrease in activity over 20 min, indicating again that no detectable time-consuming reaction occurred in these mixtures. One plausible explanation of these results is that CAC and either Factor XI or Factor XII combined very rapidly in a reaction that is not demonstrated under these circumstances and that the product of the reaction is the active species. In fact, two other reactions in the clotting sequence have been described which occur almost instantaneously: the interaction of Fac- tors IXa and VIII and the interaction of Factors X. and V (26, 27) . Interestingly, the interaction of Factors IX. and VIII reportedly can occur at glass surfaces (26) . No physiochemical evidence has been reported for a molecule that would have the properties of a complex of CAC combined with Factor XI or Factor XII, but it seems quite possible that such a complex might exist only at the glass surface and that during isolation the complex would be dissociated. Further experiments will be required to test this hypothesis.
This study has demonstrated that CAC is a unique clotting activity. Strong evidence indicates that it is the same as the recently described Fitzgerald factor. CAC promotes generation of Factor XIa in mixtures containing purified Factors XI and XII and kaolin. It appears to play an important role by limiting the amount of Factor XIa that can be generated in the mixture.
